Reply to: Ahren B et al. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13(9): 775-783 and Ahren B et al. Clinical evidence and mechanistic basis for vildagliptin's action when added to metfo